Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China:a real-world assessment  

作　　者：Yongquan Peng Xujian Cao Yating Wang Weiwei Yu Ziwei Zeng Min Wang 

机构地区：[1]Graduate Collaborative Training Base of the First Hospital of Changsha,University of South China,Hengyang,Hunan 421001,China [2]Institute of HIV/AIDS,First Hospital of Changsha,Changsha,Hunan 410000,China

出　　处：《Chinese Medical Journal》2023年第22期2738-2740,共3页中华医学杂志（英文版）

基　　金：supported by the Research project of Hunan Provincial Department of Science and Technology(No.2020SK21361)

摘　　要：To the Editor:Human immunodeficiency virus(HIV)epidemic poses a significant challenge to global public health.As of 2022,approximately 39.0 million people worldwide were living with HIV.[1]With the ongoing evolution of combined antiretroviral therapy(cART),HIV infection has transformed into a manageable chronic disease requiring long-term treatment.Among the various classes of antiretroviral(ARV)drugs,integrase strand transfer inhibitor(INSTI)-based regimens,known for potency and tolerability,have emerged as the predominant treatment modality worldwide.The nextgeneration of INSTI,bictegravir(BIC),received the Food and Drug Administration(FDA)approval in 2018 as a single-tablet regimen(STR)containing BIC(50 mg)/emtricitabine(FTC,200 mg)/tenofovir alafenamide(TAF,25 mg)for once daily.It has been endorsed as the preferred choice for treatment-naive patients by major guidelines,including the 2021 edition of the China Acquired Immune Deficiency Syndrome(AIDS)Diagnosis and Treatment Guidelines.[2]In China,people living with HIV(PLWH)are provided with flexible cART options,including the National Reimbursement Drug List(NRDL),self-pay drugs,and free drugs.Since being included in NRDL in 2021,BIC/FTC/TAF have gained popularity among an increasing number of patients.

关 键 词：REGIMEN drugs approval 

分 类 号：R512.91[医药卫生—内科学]